AdAPT-001
AXP000040.1 · Oncolytic virus
- Platform
- adenovirus (Ad5, TGF-beta trap-armed)
- Originator
- EpicentRx
- Sponsor
- EpicentRx
Names
| Name | Type | Source |
|---|---|---|
| AdAPT-001 | preferred name, code | curator, ncit |
Virus
- Role
- Oncolytic
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5 (AdAPT-001)
- Replication
- conditionally replicating
- Modifications
- armed with a TGF-beta trap
- Transgenes
- TGF-beta trap
- Route
- intratumoral
- Source
- evidence
Cross-references
- NCI Thesaurus
- C179574
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT04673942 | A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors | Active not recruiting | Phase 2 | 2021-03-29 | 2026-12-01 | 140 | Cancer; Chondrosarcoma; Neoplasms; Sarcoma; Sarcoma,Soft Tissue; Solid Tumor, Adult |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 38146006 | BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors. | Cancer gene therapy | 2024 | name in title: AdAPT-001 |
| PMID 38886116 | Hypothesis: AdAPT-001 and pseudoprogression - when seeing is not necessarily believing. | Journal for immunotherapy of cancer | 2024 | cited by trial NCT04673942 |
| PMID 39461878 | TGF-β trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistance. | Journal for immunotherapy of cancer | 2024 | cited by trial NCT04673942 |
| PMID 37008834 | Case Report of AdAPT-001-Mediated Sensitization to a Previously Failed Checkpoint Inhibitor in a Metastatic Chordoma Patient. | Case reports in oncology | 2023 | name in title: AdAPT-001 |
| PMID 35950603 | BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors. | Future oncology (London, England) | 2022 | cited by trial NCT04673942 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 37382299 | Data Management 101 for drug developers: A peek behind the curtain. | Clinical and translational science | 2023 | name in abstract: AdAPT-001 |
| PMID 35968324 | AdAPT-001, an oncolytic adenovirus armed with a TGF-β trap, overcomes in vivo resistance to PD-L1-immunotherapy. | American journal of cancer research | 2022 | name in title: AdAPT-001 |
| PMID 34765319 | Toxicology and biodistribution of AdAPT-001, a replication-competent type 5 adenovirus with a trap for the immunosuppressive cytokine, TGF-beta. | American journal of cancer research | 2021 | name in title: AdAPT-001 |
Notes
Oncolytic adenovirus carrying a TGF-beta trap transgene. Phase I/II BETA PRIME, NCT04673942, intratumoral, alone and with a checkpoint inhibitor.
How to cite
AdAPT-001 (AXP000040.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000040.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.